Business Wire

ADVA launches GPS-backup-as-a-service to help service providers combat GNSS cyberattacks

Share

ADVA (FSE: ADV) today announced that it’s enabling service provider customers to offer GPS/GNSS-backup-as-a-service (GBaaS). A wide range of industries are increasingly reliant on satellite-delivered timing, but with threats including jamming and spoofing cyberattacks on the rise, operators need to find ways to safeguard services that rely on positioning, navigation, and timing (PNT) information. In-network timing based on NTP and PTP is also increasingly vulnerable to cyber threats. As a response, ADVA is now empowering service providers to offer GBaaS and enable end users to address new guidelines and standards for redundant PNT architectures. GBaaS meets the latest recommendations for PNT homeland security like US Executive Order 13905. Leveraging ADVA’s aPNT+™ technology, it eliminates the risks and costs associated with GNSS dependence.

“Threats to hamper PNT capabilities are growing, and much of the world’s critical infrastructure is still without adequate protection from GNSS vulnerabilities. All of that can change when service providers are able to offer GBaaS. It’s based on our aPNT+ platform, which leverages a suite of technologies, including multi-band GNSS receivers and AI- and ML-based management software. As well as making networks more resilient against cyberattacks, our aPNT+ platform also delivers highly accurate backup when GNSS fails,” said Gil Biran, GM of Oscilloquartz, ADVA. “Now service providers can offer ADVA’s aPNT+protection as a subscription-based service as part of their SLAs. This will enable many more timing networks to achieve very high levels of resilience and assurance. Across a wide range of industries, this will be the easiest and most flexible way to guarantee robust PNT services.”

ADVA’s GBaaS solution employs a combination of multi-layer detection, multi-source backup and fault-tolerant mitigation to render timing networks more secure. Embedded in all timing devices, ADVA’s Syncjack technology provides comprehensive and precise synchronization performance monitoring and analytics, enabling the Ensemble Sync Director network management suite to intelligently operate and prioritize multi-source timing feeds across the network. Onboard multi-band GNSS receivers boost timing accuracy and also protect against attacks like jamming and spoofing. But for those times when GNSS is either unavailable or compromised, a dispersed network of autonomous cesium atomic clocks and network backup timing feeds is always sitting on standby, ready to deliver highly accurate network timing over long periods of GNSS unavailability.

“GBaaS is a completely new way for service providers to sell critical PNT infrastructure as a service without the burden of investment and maintenance. For the first time, they can offer their customers SLAs at a range of levels that ensure the resilient and assured timing needed across time-sensitive networks and applications,” commented Nino De Falcis, senior director of business development at Oscilloquartz, ADVA. “The flexibility and protection that GBaaS affords is bad news for any malicious actors looking to attack PNT services. Service providers can now offer their customers a guarantee: When GNSS is compromised or goes offline, ADVA’s robust network of defense-in-depth PTP timing devices will be there to provide the accuracy and backup they urgently need.”

Further information on ADVA’s GBaaS solution is available in these slides: https://adva.li/gbaas-slides.

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p